Cited by 1,099Tuberous Sclerosis Complex ResearchVascular Malformations and HemangiomasPulmonary Hypertension Research and Treatments

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

Open access

McCormack, Francis X., Inoue, Yoshikazu, Moss, Joel, Singer, Lianne G., Strange, Charlie, Nakata, Koh, Barker, Alan F., Chapman, Jeffrey T., Brantly, Mark L., Stocks, James M., Brown, Kevin K., Lynch, Joseph P., Goldberg, Hilary J., Young, Lisa R., Kinder, Brent W., Downey, Gregory P., Sullivan, Eugene J., Colby, Thomas V., McKay, Roy T., Cohen, Marsha M., Korbee, Leslie, Taveira-DaSilva, Angelo M., Lee, Hye-Seung, Krischer, Jeffrey P., Trapnell, Bruce C.·2011·New England Journal of Medicine

DOI 10.1056/nejmoa1100391PMC PMC3118601

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM. METHODS: We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment--a 12-month randomized, double-blind comparison of sirolimus with placebo, followed by a 12-month observation period. The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory volume in 1 second (FEV(1)). RESULTS: During the treatment period, the FEV(1) slope was -12±2 ml per month in the placebo group (43 patients) and 1±2 ml per month in the sirolimus group (46 patients) (P<0.001). The absolute between-group difference in the mean change in FEV(1) during the treatment period was 153 ml, or approximately 11% of the mean FEV(1) at enrollment. As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance. There was no significant between-group difference in this interval in the change in 6-minute walk distance or diffusing capacity of the lung for carbon monoxide. After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group. Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups. CONCLUSIONS: In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life. Therapy with sirolimus may be useful in selected patients with LAM. (Funded by the National Institutes of Health and others; MILES ClinicalTrials.gov number, NCT00414648.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1100391

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,275
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,250
Self-citation
A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 674
Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis
Carsillo, T., Astrinidis, A., & Henske, E. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6085 · Cited by 648
Minimal Clinically Important Differences in COPD Lung Function
Donohue, J. F. (2005) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200053377 · Cited by 525
The truly remarkable universality of half a standard deviation: confirmation through another look
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2004) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.4.5.581 · Cited by 490
The NHLBI Lymphangioleiomyomatosis Registry
Ryu, J. H., Moss, J., Beck, G. J., Lee, J.-C., Brown, K. K., Chapman, J. T., Finlay, G. A., Olson, E. J., Ruoss, S. J., MAURER, J. R., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200409-1298oc · Cited by 466
Self-citation
Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation
Goncharova, E., Goncharov, D. A., Eszterhas, A., Hunter, D., Glassberg, M., Yeung, R. S., Walker, C., Noonan, D., Kwiatkowski, D., Chou, M. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202678200 · Cited by 433
Pulmonary Lymphangioleiomyomatosis: A Study of 69 Patients
Urban, T., Lazor, R., Lacronique, J., Murris, M., Labrune, S., & Valeyre, D. (1999) · Medicine · doi:10.1097/00005792-199909000-00004 · Cited by 327
Lymphangioleiomyomatosis
McCormack, F. X. (2008) · CHEST Journal · doi:10.1378/chest.07-0898 · Cited by 303
Self-citation

Flagged first, then by citations

Show all 27 references

Research works printed but not linked: 1

Khanna D, 2010, Clin Exp Rheumatol, 28, S55

Sorted by citations

Items 301–400 of 999

Lymphangioleiomyomatosis: a metastatic lung disease
Kundu, N., & Holz, M. K. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00202.2022 · Cited by 25
The world of rare interstitial lung diseases
Buschulte, K., Cottin, V., Wijsenbeek, M. S., Kreuter, M., & Diesler, R. (2023) · European Respiratory Review · doi:10.1183/16000617.0161-2022 · Cited by 26
mTOR treatment in lymphangioleiomyomatosis: the role of everolimus
Yates, D. H. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1148603 · Cited by 25
Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study
Zhan, Y., Shen, L., Xu, W., Wu, X., Zhang, W., Wang, J., Li, X., Yang, Y., Tian, X., & Xu, K. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0775-9 · Cited by 25
A Clinical Approach to Diffuse Parenchymal Lung Disease
Maher, T. M. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.08.004 · Cited by 25
Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage
Xu, K., Tian, X., Yang, Y., & Zhang, H. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-211135 · Cited by 25
Targeted Approaches toward Understanding and Treating Pulmonary Lymphangioleiomyomatosis (LAM)
Hammes, S. R., & Krymskaya, V. P. (2012) · Hormones and Cancer · doi:10.1007/s12672-012-0128-4 · Cited by 24
Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge
McCarthy, C., Gallego, B. L., Trapnell, B. C., & McCormack, F. X. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67144-4_24 · Cited by 24
Self-citation
Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial
Wataya‐Kaneda, M., Nagai, H., Ohno, Y., Yokozeki, H., Fujita, Y., Niizeki, H., Yoshida, K., Ogai, M., Yoshida, Y., Asahina, A., et al. (2020) · Dermatology and Therapy · doi:10.1007/s13555-020-00387-7 · Cited by 24
Rare Lung Disease Research
Gupta, S., Bayoumi, A. M., & Faughnan, M. E. (2011) · CHEST Journal · doi:10.1378/chest.11-1094 · Cited by 24
EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex
Fogarasi, A., Waele, L. D., Bartalini, G., Jóźwiak, S., Laforgia, N., Verhelst, H., Petrak, B., Pédespan, J., Witt, O., Castellana, R., et al. (2016) · BMC Neurology · doi:10.1186/s12883-016-0658-4 · Cited by 24
Estimating the concentration of therapeutic range using disease-specific iPS cells: Low-dose rapamycin therapy for Pendred syndrome
Hosoya, M., Saeki, T., Saegusa, C., Matsunaga, T., Okano, H., Fujioka, M., & Ogawa, K. (2018) · Regenerative Therapy · doi:10.1016/j.reth.2018.11.001 · Cited by 24
RETRACTED: Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion
Zarei, M., Du, H., Nassar, A. H., Yan, R., Giannikou, K., Johnson, S. H., Lam, H. C., Henske, E. P., Wang, Y., Zhang, T., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190251 · Cited by 23
Retracted
Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives
Willems, L. M., Rosenow, F., Schubert‐Bast, S., Kurlemann, G., Zöllner, J. P., Bast, T., Bertsche, A., Bettendorf, U., Ebrahimi‐Fakhari, D., Grau, J., et al. (2021) · CNS Drugs · doi:10.1007/s40263-021-00839-4 · Cited by 23
Women with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis
Marco, F. D., Terraneo, S., Imeri, G., Palumbo, G., Briola, F. L., Tresoldi, S., Volpi, A., Gualandri, L., Ghelma, F., Alfano, R. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155331 · Cited by 24
The Progress of Mitophagy and Related Pathogenic Mechanisms of the Neurodegenerative Diseases and Tumor
Song, Y., Ding, W., Xiao, Y. C., & Lu, K.-J. (2015) · Neuroscience Journal · doi:10.1155/2015/543758 · Cited by 23
Tuberous sclerosis—A model for tumour growth
Dodd, K. M., & Dunlop, E. A. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.01.025 · Cited by 23
YouTube-videos for patient education in lymphangioleiomyomatosis?
Wilkens, F. M., Ganter, C., Kriegsmann, K., Wilkens, H., Kahn, N. C., Goobie, G. C., Ryerson, C. J., & Kreuter, M. (2022) · Respiratory Research · doi:10.1186/s12931-022-02022-9 · Cited by 23
Evaluation of the Extent of Pulmonary Cysts and Their Association with Functional Variables and Serum Markers in Lymphangioleiomyomatosis (LAM)
Baldi, B. G., Araújo, M. S., Freitas, C. S. G., Teles, G. B. D. S., Kairalla, R. A., Dias, O. M., Pereira, D. A. S., Pimenta, S. P., & de Carvalho, C. R. R. (2014) · Lung · doi:10.1007/s00408-014-9641-2 · Cited by 23
Enhanced Antitumor Activity of 3-Bromopyruvate in Combination with Rapamycin In Vivo and In Vitro
Zhang, Q., Pan, J., Lubet, R. A., Komas, S. M., Kalyanaraman, B., Wang, Y., & You, M. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0142 · Cited by 23
Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis
Li, C., Zhang, E. Y., Sun, Y., Lee, P., Zhan, Y., Guo, Y., Osorio, J. C., Rosas, I. O., Xu, K., Kwiatkowski, D. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104809 · Cited by 23
Mesenchymal Tumorigenesis Driven by TSC2 Haploinsufficiency Requires HMGA2 and Is Independent of mTOR Pathway Activation
D'Armiento, J. M., Shiomi, T., Marks, S., Geraghty, P. M., Sankarasharma, D., & Chada, K. K. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1287 · Cited by 23
Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?
Weatherald, J. C., Savale, L., & Humbert, M. J. C. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0783-5 · Cited by 23
Multiple Cystic Lung Disease
Koo, H., & Yoo, C. (2013) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2013.74.3.97 · Cited by 23
Management of the “Other” retroperitoneal sarcomas
Rutkowski, P. L., & Mullen, J. T. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24893 · Cited by 23
Diffuse Cystic Lung Disease
Franciosi, A. N., Gupta, N., Murphy, D. J., Wikenheiser‐Brokamp, K. A., & McCarthy, C. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.08.008 · Cited by 22
Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience
Revilla‐López, E., Berastegui, C., Méndez, A., Sáez, B., de Miguel, V. R., López‐Meseguer, M., Monforte, V., Bravo, C., Pujana, M. Á., Ramón, M. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89562-0 · Cited by 24
Evolução da função pulmonar após tratamento com goserelina em pacientes com linfangioleiomiomatose
Baldi, B. G., Medeiros, P., Pimenta, S. P., Lopes, R. I., Kairalla, R. A., & de Carvalho, C. R. R. (2011) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132011000300015 · Cited by 22
Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis
Lamattina, A. M., Taveira‐DaSilva, A. M., Goldberg, H. J., Bagwe, S., Cui, Y., Rosas, I. O., Moss, J., Henske, E. P., & El‐Chemaly, S. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.08.1029 · Cited by 22
Self-citation
Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis
Yoon, H., Hwang, J. J., Kim, D. S., & Song, J. W. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0946-8 · Cited by 22
Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis
Herranz, C., Mateo, F., Baiges, A., Ponce, G. R. D. G., Junza, A., Johnson, S. R., Miller, S., García, N., Capellades, J., Gómez, A., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202113929 · Cited by 21
Sirolimus Is a Successful Treatment for Recurrent Iron Deficiency Anaemia in Blue Rubber Bleb Naevus Syndrome
Warner, B. D., Butt, A. M., & Cairns, S. R. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000247 · Cited by 21
The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models
Steagall, W. K., Pacheco–Rodriguez, G., Darling, T. N., Torre, O., Harari, S. A., & Moss, J. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0403tr · Cited by 21
Self-citation
Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells
Tang, Y., El‐Chemaly, S., Taveira‐DaSilva, A. M., Goldberg, H. J., Bagwe, S., Rosas, I. O., Moss, J., Priolo, C., & Henske, E. P. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.05.038 · Cited by 19
Self-citation
A current perspective on the role for molecular studies in soft tissue tumor pathology
Tos, A. P. D. (2013) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2013.11.003 · Cited by 20
Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer
El‐Chemaly, S., & Henske, E. P. (2014) · European Respiratory Review · doi:10.1183/09059180.00008813 · Cited by 20
A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex
Krymskaya, V. P., Courtwright, A., Fleck, V., Dorgan, D. J., Kotloff, R. M., McCormack, F. X., & Kreider, M. E. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.105898 · Cited by 20
Self-citation
Ultra-rare cystic disease
Elia, D., Torre, O., Cassandro, R., Caminati, A., & Harari, S. A. (2020) · European Respiratory Review · doi:10.1183/16000617.0163-2019 · Cited by 20
Sirolimus in the Treatment of Microcystic Lymphatic Malformations: A Systematic Review
Teng, J. M. C., Hammill, A. M., Martini, J., & Treat, J. R. (2022) · Lymphatic Research and Biology · doi:10.1089/lrb.2021.0103 · Cited by 20
Imaging Findings of Thoracic Lymphatic Abnormalities
Sun, J. D., Shum, T., Behzadi, F., & Hammer, M. M. (2022) · Radiographics · doi:10.1148/rg.220040 · Cited by 20
Targeted Therapies in Rare Sarcomas
Stacchiotti, S., Marrari, A., Tos, A. P. D., & Casali, P. G. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.07.009 · Cited by 20
Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2 -null cell survival
Campos, T., Ziehe, J., Fuentes‐Villalobos, F., Riquelme, O., Peña, D., Troncoso, R., Lavandero, S., Morı́n, V., Pincheira, R., & Castro, A. F. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.009 · Cited by 20
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation
Cui, Y., Steagall, W. K., Lamattina, A. M., Pacheco–Rodriguez, G., Stylianou, M. P., Kidambi, P., Stump, B., Golzarri, M. F., Rosas, I. O., Priolo, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2755 · Cited by 20
Self-citation
Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development
Jeong, A., & Wong, M. (2017) · Journal of Child Neurology · doi:10.1177/0883073817696814 · Cited by 18
Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis
Filippakis, H., Belaïd, A., Siroky, B. J., Wu, C., Alesi, N., Hougard, T. R., Nijmeh, J., Lam, H. C., & Henske, E. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-32256-x · Cited by 19
mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development
Molina, L. M., Yang, H., Michael, A. O. A., Oertel, M., Bell, A. W., Singh, S., Chen, X., Tao, J., & Monga, S. P. (2019) · Oncotarget · doi:10.18632/oncotarget.26668 · Cited by 20
Berunda Polypeptides: Biheaded Rapamycin Carriers for Subcutaneous Treatment of Autoimmune Dry Eye Disease
Lee, C., Guo, H., Klinngam, W., Janga, S. R., Yarber, F., Peddi, S., Edman, M. C., Tiwari, N. R., Liu, S., Louie, S. G., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00263 · Cited by 20
Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer
Kim, E. Y., Lee, J. G., Lee, J. M., Kim, A., Yoo, H. C., Kim, K., Lee, M., Lee, C., Han, G., Han, J. M., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919846798 · Cited by 21
Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis
Liu, H.-J., Krymskaya, V. P., & Henske, E. P. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.08.005 · Cited by 22
Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop
Henske, E. P., Rasooly, R. S., Siroky, B. J., & Bissler, J. J. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00525.2013 · Cited by 20
Current Options for the Treatment of Facial Angiofibromas
Salido‐Vallejo, R., Garnacho-Saucedo, G. M., & Moreno‐Giménez, J. C. (2014) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2014.05.001 · Cited by 20
Characteristics of Patients with Lymphangioleiomyomatosis and Pleural Effusion: A Systematic Review
Lama, A., Ferreiro, L., Golpe, A., Gudé, F., Álvarez-Dobaño, J. M., González‐Barcala, F. J., Toubes, M. E., José, E. S., Rodríguez‐Núñez, N., & Valdés, L. (2016) · Respiration · doi:10.1159/000444264 · Cited by 20
Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy
Franz, D. N., & Capal, J. K. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s91248 · Cited by 20
Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing Lgals3
Klover, P. J., Thangapazham, R. L., Kato, J., Wang, J.-A., Anderson, S. A., Hoffmann, V. J., Steagall, W. K., Li, S., McCart, E. A., Nathan, N. R., et al. (2017) · eLife · doi:10.7554/elife.23202 · Cited by 20
Self-citation
Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results
Capal, J. K., Ritter, D. M., Franz, D. N., Griffith, M. S., Currans, K., Kent, B., Bebin, E. M., Northrup, H., Koenig, M. K., Mizuno, T., et al. (2024) · Annals of the Child Neurology Society · doi:10.1002/cns3.20070 · Cited by 20
Calorie restriction mimetic drugs could favorably influence gut microbiota leading to lifespan extension
Shintani, T., Shintani, H., Sato, M., & Ashida, H. (2023) · GeroScience · doi:10.1007/s11357-023-00851-0 · Cited by 19
Hemispheric epilepsy surgery for hemimegalencephaly: The UCLA experience
Goël, K., Phillips, H. W., Chen, J., Ngo, J., Edmonds, B. D., Ha, P. X., Wang, A., Weil, A. G., Russell, B. E., Salamon, N., et al. (2023) · Epilepsia · doi:10.1111/epi.17807 · Cited by 19
Lymphangioleiomyomatosis: A Review
Bouanzoul, M. A., & Rosen, Y. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2024-0206-ra · Cited by 19
Optimizing treatments for lymphangioleiomyomatosis
Taveira‐DaSilva, A. M., & Moss, J. (2012) · Expert Review of Respiratory Medicine · doi:10.1586/ers.12.26 · Cited by 19
Self-citation
mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?
Kwiatkowski, D., & Wagle, N. (2014) · EBioMedicine · doi:10.1016/j.ebiom.2014.12.011 · Cited by 15
Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness
Ponce, G. R. D. G., Herranz, C., Lope, A. L., Boni, J., Serra-Musach, J., Mateo, F., Aguilar, H., Gómez‐Baldó, L., Petit, A., Vidal, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132546 · Cited by 19
Effect of beta-agonists on LAM progression and treatment
Le, K., Steagall, W. K., Stylianou, M. P., Pacheco–Rodriguez, G., Darling, T. N., Vaughan, M. M., & Moss, J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719960115 · Cited by 19
Self-citation
The vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis
Miller, S., Coveney, C., JOHNSON, J. H., Farmaki, A., Gupta, N., Tobin, M. D., Wain, L. V., McCormack, F. X., Boocock, D. J., & Johnson, S. R. (2018) · European Respiratory Journal · doi:10.1183/13993003.00951-2018 · Cited by 20
Self-citation
MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61
Zarei, M., Giannikou, K., Du, H., Liu, H.-J., Duarte, M., Johnson, S. H., Nassar, A. H., Widlund, H. R., Henske, E. P., Long, H. W., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01504-8 · Cited by 21
Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model
Prabhakar, S., Zhang, X., Goto, J., Han, S., Lai, C. P., Bronson, R. T., Sena‐Esteves, M., Ramesh, V., Stemmer-Rachamimov, A. O., Kwiatkowski, D. J., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.018 · Cited by 19
Forging Stronger Partnerships Between Academic Health Centers and Patient-Driven Organizations
Gallin, E. K., Bond, E. C., Califf, R. M., Crowley, W. F., Davis, P., Galbraith, R. A., & Reece, E. A. (2013) · Academic Medicine · doi:10.1097/acm.0b013e31829ed2a7 · Cited by 19
In situ analysis of mTORC1/2 and cellular metabolism–related proteins in human Lymphangioleiomyomatosis
Krencz, I., Sebestyén, A. R., Pápay, J., Jeney, A., Hujber, Z., Burger, C. D., Keller, C. A., & Khoór, A. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.05.018 · Cited by 19
mTORC1 Activation by Loss of Tsc1 in Myelinating Glia Causes Downregulation of Quaking and Neurofascin 155 Leading to Paranodal Domain Disorganization
Shi, Q., Saifetiarova, J., Taylor, A. M., & Bhat, M. A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00201 · Cited by 19
Mammalian Target of Rapamycin: A Target for (Lung) Diseases and Aging
Kennedy, B. K., & Pennypacker, J. K. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201609-680aw · Cited by 18
Lymphangioleiomyomatosis (LAM) Cell Atlas
Du, Y., Guo, M., Wu, Y., Wagner, A. J., Perl, A. T., Wikenheiser‐Brokamp, K. A., Yu, J. J., Gupta, N., Kopras, E. J., Krymskaya, V. P., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2022-218772 · Cited by 18
Self-citation
Ultra-low dose chest CT with silver filter and deep learning reconstruction significantly reduces radiation dose and retains quantitative information in the investigation and monitoring of lymphangioleiomyomatosis (LAM)
Golbus, A. E., Steveson, C., Schuzer, J. L., Rollison, S. F., Worthy, T., Jones, A. M., Julien-Williams, P. A., Moss, J., & Chen, M. Y. (2024) · European Radiology · doi:10.1007/s00330-024-10649-z · Cited by 18
Self-citation
Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug Targets
Conte, E., Boccanegra, B., Dinoi, G., Pusch, M., Luca, A. D., Liantonio, A., & Imbrici, P. (2024) · Biomolecules · doi:10.3390/biom14091190 · Cited by 19
Anti-EGFR Antibody Reduces Lung Nodules by Inhibition of EGFR-Pathway in a Model of Lymphangioleiomyomatosis
Lesma, E. A., Chiaramonte, E., Ancona, S., Orpianesi, E., Giulio, A. M. D., & Gorio, A. (2015) · BioMed Research International · doi:10.1155/2015/315240 · Cited by 18
A Quantitative Proteomic Approach to Identify Significantly Altered Protein Networks in the Serum of Patients with Lymphangioleiomyomatosis (LAM)
Banville, N., Burgess, J. K., Jaffar, J., Tjin, G., Richeldi, L., Cerri, S., Persiani, E., Black, J. L., & Oliver, B. G. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105365 · Cited by 18
Cystic lung disease
Clarke, B. E. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201297 · Cited by 18
St. George's Respiratory Questionnaire Has Longitudinal Construct Validity in Lymphangioleiomyomatosis
Swigris, J. J., Lee, H., Cohen, M. M., Inoue, Y., Moss, J., Singer, L. G., Young, L. R., & McCormack, F. X. (2013) · CHEST Journal · doi:10.1378/chest.12-0161 · Cited by 18
Self-citation
A Current Viewpoint of Lymphangioleiomyomatosis Supporting Immunotherapeutic Treatment Options
Dilling, D. F., Gilbert, E. R., Picken, M. M., Eby, J. M., Love, R. B., & Poole, I. C. L. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0215tr · Cited by 18
Sirolimus Therapy as Perioperative Treatment of Gorham-Stout Disease in the Thoracic Spine
Mo, A. Z., Trenor, C. C., & Hedequist, D. (2018) · JBJS Case Connector · doi:10.2106/jbjs.cc.17.00287 · Cited by 18
Cellular and molecular mechanisms of PIK3CA-related vascular anomalies
Cras, T. D. L., & Boscolo, E. (2019) · Vascular Biology · doi:10.1530/vb-19-0016 · Cited by 18
mTORC1 is a mechanosensor that regulates surfactant function and lung compliance during ventilator-induced lung injury
Lee, H., Fei, Q., Streicher, A., Zhang, W., Isabelle, C., Patel, P., Lam, H. C., Arciniegas, A. J. L., Pinilla-Vera, M., Amador-Munoz, D. P., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.137708 · Cited by 21
Self-citation
Angiomyomatous hamartoma of lymph nodes, revisited: clinicopathologic study of 21 cases, emphasizing its distinction from lymphangioleiomyomatosis of lymph nodes
Moh, M., Sangoi, A. R., & Rabban, J. T. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.08.035 · Cited by 18
Recurrence of lymphangioleiomyomatosis: nine years after a bilateral lung transplantation
Zaki, K. S., Aryan, Z., Mehta, A. C., Akindipe, O., & Budev, M. (2016) · World Journal of Transplantation · doi:10.5500/wjt.v6.i1.249 · Cited by 17
Giant Bilateral Renal Angiomyolipomas and Lymphangioleiomyomatosis Presenting after Two Successive Pregnancies Successfully Treated with Surgery and Rapamycin
Peces, R., Cuesta-López, E., Peces, C., & Selgas, R. (2011) · The Scientific World JOURNAL · doi:10.1100/2011/263137 · Cited by 17
Isolation and characterisation of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis
Nishino, K., Yoshimatsu, Y., Muramatsu, T., Sekimoto, Y., Mitani, K., Kobayashi, E., Okamoto, S., Ebana, H., Okada, Y., Kurihara, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88064-3 · Cited by 17
Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results
Rojas, M. L. R.-F., Feucht, M., Macaya, A., Wilken, B., Hahn, A., Maamari, R., Hirschberg, Y., Ridolfi, A., & Kingswood, J. C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.802334 · Cited by 17
Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database
Boggarapu, S., Roberds, S. L., Nakagawa, J., & Beresford, E. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02496-2 · Cited by 17
French recommendations for the diagnosis and management of lymphangioleiomyomatosis
Cottin, V., Blanchard, É., Kerjouan, M., Lazor, R., Reynaud‐Gaubert, M., Taillé, C., Uzunhan, Y., Wémeau-Stervinou, L., Andréjak, C., Baud, D., et al. (2023) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2023.101010 · Cited by 17
Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis
Gibbons, E. P., Taya, M., Wu, H., Lopa, S., Moss, J., Henske, E. P., McCormack, F. X., & Hammes, S. R. (2024) · Endocrine Related Cancer · doi:10.1530/erc-23-0312 · Cited by 17
Self-citation
Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis
Stuijver, D. J. F., Romualdi, E., van Zaane, B., Bax, L., Buller, H. R., Gerdes, V. E. A., & Squizzato, A. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1168-2 · Cited by 17
Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex
Moavero, R., Romagnoli, G., Graziola, F., & Curatolo, P. (2015) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2015.10.006 · Cited by 17
Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells
Harari, S. A., Elia, D., Torre, O., Bulgheroni, E., Provasi, E., & Moss, J. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.02.654 · Cited by 17
Self-citation
New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND)
Gipson, T., & Johnston, M. V. (2017) · F1000Research · doi:10.12688/f1000research.11110.1 · Cited by 17
Facilitating Clinical Studies in Rare Diseases
Gopal-Srivastava, R., & Kaufmann, P. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67144-4_6 · Cited by 17
Smoking-Related Diffuse Cystic Lung Disease
Gupta, N., Colby, T. V., Meyer, C. A., McCormack, F. X., & Wikenheiser‐Brokamp, K. A. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.02.027 · Cited by 17
Self-citation
Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis
Bottolo, L., Miller, S., & Johnson, S. R. (2020) · Thorax · doi:10.1136/thoraxjnl-2019-214241 · Cited by 16
Treatment of Aggressive Retinal Astrocytic Hamartoma with Oral Mechanistic Target of Rapamycin Inhibition
Wu, F., McGarrey, M. P., Geenen, K. R., Skalet, A. H., Guillot, F. H., Wilson, J. L., Shah, A. S., Gonzalez, J. E., Thiele, E. A., Kim, I. K., et al. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.01.003 · Cited by 17
Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans
Hagan, M. J., Shenkar, R., Srinath, A., Romanos, S. G., Stadnik, A., Kahn, M. L., Marchuk, D. A., Girard, R., & Awad, I. A. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00006 · Cited by 17
Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis
Malinowska, I. A., Lee, N. Y., Kumar, V., Thiele, E. A., Franz, D. N., Ashwal, S., Sagalowsky, A. I., DiMario, F. J., Cutler, D., Krueger, D. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056199 · Cited by 17
Rapamycin decreases airway remodeling and hyperreactivity in a transgenic model of noninflammatory lung disease
Kramer, E. L., Hardie, W. D., Mushaben, E. M., Acciani, T. H., Pastura, P. A., Korfhagen, T. R., Hershey, G. K. K., Whitsett, J. A., & Cras, T. D. L. (2011) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00737.2011 · Cited by 17
Tuberin Regulates Prostaglandin Receptor–Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells
Li, C., Liu, X., Yang, L., Zhang, E. Y., Medepalli, K., Masuda, K., Li, N., Wikenheiser‐Brokamp, K. A., Osterburg, A. R., Borchers, M. T., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0077 · Cited by 17

Authors: McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., Brown, K. K., Lynch, J. P., Goldberg, H. J., Young, L. R., Kinder, B. W., Downey, G. P., Sullivan, E. J., Colby, T. V., McKay, R. T., Cohen, M. M., Korbee, L., Taveira-DaSilva, A. M., Lee, H.-S., Krischer, J. P., & Trapnell, B. C.
Affiliations: University of Cincinnati (US)
National Hospital Organization (JP)
National Institutes of Health (US)
University of Toronto (CA)
Medical University of South Carolina (US)
Niigata University Medical and Dental Hospital (JP)
Oregon Health & Science University (US)
Cleveland Clinic (US)
University of Florida (US)
The University of Texas Health Science Center at Tyler (US)
National Jewish Health (US)
Cincinnati Children's Hospital Medical Center (US)
Harvard University (US)
United Therapeutics (United States) (US)
Mayo Clinic (US)
University of South Florida (US)
ORCID: McCormack, Francis X.
Inoue, Yoshikazu
Moss, Joel
Singer, Lianne G.
Strange, Charlie
Nakata, Koh
Brantly, Mark L.
Brown, Kevin K.
Goldberg, Hilary J.
Young, Lisa R.
Downey, Gregory P.
Colby, Thomas V.
Lee, Hye-Seung
Krischer, Jeffrey P.
Trapnell, Bruce C.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2011-04-28
Volume: 364
Issue: 17
Pages: 1595-1606
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1100391
PMC: PMC3118601
OpenAlex: W2147028601
Semantic Scholar: 0af4a52c455e626ae3c70aa2ba2d64208b19a305
Cited by: 1,099
References: 27
Citations by year: 2026: 38 · 2025: 54 · 2024: 77 · 2023: 70 · 2022: 80 · 2021: 70 · 2020: 72 · 2019: 78 · 2018: 77 · 2017: 65 · 2016: 78 · 2015: 87 · 2014: 71 · 2013: 81 · 2012: 68
FWCI: 54.96
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Tuberous Sclerosis Alliance
Pfizer
LAM Foundation
Cincinnati Children's Hospital Medical Center
National Institutes of Health (1ul1rr026314-01, 1UL1RR026314)
U.S. Food and Drug Administration (FD003362, R01 FD003362)
Canadian Institutes of Health Research
National Heart, Lung, and Blood Institute (R01HL085453, ZIAHL002541)
National Center for Research Resources (1UL1 RR-026314-01, U54RR019259, UL1-RR026314, U54RR019498, RR019498, RR019259)
NHLBI Division of Intramural Research
Topics: Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
Health Sciences › Medicine › Surgery › Vascular Malformations and Hemangiomas
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords: lymphangioleiomyomatosis, rapamycin, mTOR signaling, lung function, FEV1, VEGF-D, quality of life, adverse events, drug discontinuation, cystic lung disease
MeSH terms: Adult, Double-Blind Method, Female, Forced Expiratory Volume, Humans, Middle Aged, Quality of Life, Vital Capacity, Lymphangioleiomyomatosis, Observation, Sirolimus, Medication Adherence, Intention to Treat Analysis, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks